Takeda (TAK) and Protagonist Therapeutics (PTGX) announced the submission of a new drug application to the FDA seeking approval of rusfertide for the treatment of adults with polycythemia vera. Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell production to control hematocrit levels in patients with PV.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TAK:
- H.C. Wainwright remains bullish on Xoma following creative Takeda deal
- Xoma, Takeda execute royalty sharing transaction, amend Mezagitamab agreement
- Leerink says Takeda results signal positive readthrough for Alumis
- Alumis price target raised to $20 from $14 at H.C. Wainwright
- Takeda announces zasocitinib studies met primary, secondary endpoints